Objective: To examine resilience as a predictor of change in self-reported fatigue after mild traumatic brain injury (MTBI).
Participants: A consecutive series of 67 patients with MTBI and 34 orthopedic controls.
Design: Prospective longitudinal study.
Main Measures: Resilience Scale, Beck Depression Inventory-Second Edition, and Pain subscale from Ruff Neurobehavioral Inventory 1 month after injury and Barrow Neurological Institute Fatigue Scale 1 and 6 months after injury.
Results: Insomnia, pain, and depressive symptoms were significantly correlated with fatigue, but even when these variables were controlled for, resilience significantly predicted the change in fatigue from 1 to 6 months after MTBI. In patients with MTBI, the correlation between resilience and fatigue strengthened during follow-up. In controls, significant associations between resilience and fatigue were not found.
Conclusion: Resilience is a significant predictor of decrease in self-reported fatigue following MTBI. Resilience seems to be a relevant factor to consider in the management of fatigue after MTBI along with the previously established associated factors (insomnia, pain, and depressive symptoms).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/HTR.0000000000000055 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Factors affecting fatigue progression in multiple sclerosis patients.
Sci Rep
December 2024
Nehme and Therese Tohme Multiple Sclerosis Center, American University of Beirut Medical Center, Riad El-Solh, PO Box 11-0236, 1107 2020, Beirut, Lebanon.
Fatigue is one of the most prevalent and disabling symptoms among patients with MS, but there is limited research investigating the longitudinal determinants of fatigue progression. This study aims to identify the sociodemographic, behavioral and clinical characteristics, and therapeutic regimens that are correlated with worsening fatigue over time in patients diagnosed with MS. This is a retrospective chart review of 483 patients.
View Article and Find Full Text PDFResearch progress and treatment status of malignant ascites.
Front Oncol
December 2024
Department of Oncology, Guang'anmen Hospital Jinan Hospital (Jinan Hospital of Traditional Chinese Medicine), Jinan, China.
Malignant ascites (MA), a common and serious complication of various cancers in the abdominal cavity, originates from the extensive infiltration, metastasis, and growth of cancer cells in or on the abdominal cavity, leading to abnormal accumulation of fluid in the abdominal cavity and the formation of MA. MA seriously reduces the quality of life of cancer patients, shortens their survival period, and generally has a poor prognosis. Modern medicine has developed various strategies for the treatment of MA, including targeted supportive treatment, diuretic treatment, abdominal paracentesis, surgical intervention, and intraperitoneal administration therapy.
View Article and Find Full Text PDFA phase I study using bortezomib (Velcade), cladribine, and rituximab in treating patients over 50 years old with mantle cell lymphoma.
Front Oncol
December 2024
Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, United States.
Unlabelled: Cladribine indirectly downregulates methylation of DNA, RNA, and histones by blocking the transfer of methyl groups from -adenosyl-methionine. The cladribine and rituximab combination showed a synergetic effect in treating B-cell lymphomas. Bortezomib (Velcade) is a Food and Drug Administration (FDA)-approved proteasome inhibitor for treating mantle cell lymphoma (MCL).
View Article and Find Full Text PDFObjectives Diabetes mellitus type 2 is a chronic metabolic disorder characterized by insulin resistance and progressive beta-cell dysfunction. As diabetes persists over time, more pronounced symptoms like polyuria, polydipsia, fatigue, and complications like neuropathy, retinopathy, and cardiovascular issues may develop. Therefore, this study assessed the clinical symptoms associated with type 2 diabetes regarding the duration of diabetes.
View Article and Find Full Text PDFOverlap syndrome of Erdheim-Chester disease and Langerhans cell histiocytosis: A case report.
Cytojournal
November 2024
Department of Hematology, Zhongshan City People's Hospital, Zhongshan, Guangdong, China.
Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) are exceptionally rare disorders characterized by varied clinical presentations, posing several challenges for clinicians. The concomitant occurrence of LCH and ECD is exceedingly rare and has no known etiology. In this report, we present a rare case of mixed histiocytosis (both ECD and LCH) with multisystem involvement.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!